What Is Semaglutide? The Science Explained

TL;DR: Semaglutide is an FDA-approved prescription GLP-1 receptor agonist available under the brand names Ozempic, Wegovy, and Rybelsus. It works by mimicking the incretin hormone GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and signaling satiety in the brain. A fatty-acid acylation modification extends its half-life to approximately one week. The SUSTAIN clinical trial program established its glycemic profile in type 2 diabetes; the STEP program documented its weight-management effects. This article is a science explainer only, not medical advice, not dosing guidance, and not a recommendation to use or seek this medication.

Important Notice: Semaglutide is an FDA-approved prescription medication. It is not a research chemical, not available without a prescription, and not suitable for self-directed use outside of medical supervision. This article documents the published science behind semaglutide’s mechanism and clinical evidence base for educational and research reference purposes only. Nothing in this article constitutes medical advice, recommends a course of treatment, or substitutes for evaluation by a licensed healthcare professional. Must be 21+.

What Is Semaglutide? Definition and Prescription Status

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of prescription medication that acts by binding to and activating GLP-1 receptors throughout the body. It is an analogue of the naturally occurring incretin hormone GLP-1, engineered for extended pharmacological activity. Semaglutide is sold under three brand names in the United States:

• Ozempic, subcutaneous injection, approved for glycemic control in type 2 diabetes and to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease
• Wegovy, higher-dose subcutaneous injection, approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
• Rybelsus, oral tablet, approved for glycemic control in type 2 diabetes, the first orally administered GLP-1 receptor agonist to reach market

All three formulations require a valid prescription from a licensed prescriber. Semaglutide is manufactured by Novo Nordisk and is not available over the counter or as a dietary supplement. Any discussion of semaglutide in a clinical context belongs between a patient and their healthcare provider.

What Is the Incretin Mechanism and How Does GLP-1 Fit In?

To understand semaglutide, it is necessary to understand incretins, gut-derived hormones that amplify insulin secretion in response to nutrient ingestion. The incretin effect accounts for a significant portion of postprandial insulin release; it is substantially reduced in type 2 diabetes, which is a key reason the class of GLP-1 receptor agonists attracted clinical interest.

What Is GLP-1 and What Does It Do Natively?

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide secreted by L-cells in the distal small intestine and colon in response to food ingestion. Native GLP-1 has a plasma half-life of approximately 1–2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4) and renal clearance, making it unsuitable as a therapeutic agent in its unmodified form. Pharmacologically, GLP-1 receptor activation produces four coordinated effects:

1. Glucose-dependent insulin secretion, GLP-1 receptor agonism stimulates pancreatic beta cells to release insulin, but only when blood glucose is elevated. This glucose-dependency is a key safety feature: insulin release is not triggered when glucose is normal or low, which substantially limits the risk of hypoglycemia compared to sulfonylureas or insulin.
2. Glucagon suppression, GLP-1 receptor activation suppresses glucagon secretion from pancreatic alpha cells (again, in a glucose-dependent manner), reducing hepatic glucose output during the postprandial period.
3. Delayed gastric emptying, GLP-1 receptor agonism slows the rate at which stomach contents empty into the small intestine, blunting the postprandial glucose spike and contributing to satiety.
4. Central satiety signaling, GLP-1 receptors are expressed in hypothalamic regions involved in appetite regulation. Activation of these receptors decreases appetite and energy intake, an effect that is central to semaglutide’s role in weight management.

A 2019 review by Aroda et al. in Diabetes & Metabolism, covering the full SUSTAIN 1–7 trial program, described semaglutide as working “via the incretin pathway, stimulating insulin and inhibiting glucagon secretion from the pancreatic islets, leading to lower blood glucose levels, ” while also decreasing energy intake by reducing appetite and food cravings. [DOI: 10.1016/j.diabet.2018.12.001]

How Was Semaglutide Engineered to Last One Week?

Native GLP-1 is pharmacologically inert as a drug candidate because it is degraded within minutes. Semaglutide’s development by Novo Nordisk required solving a half-life engineering problem: how to preserve the GLP-1 receptor agonism while dramatically extending plasma residence time to allow weekly dosing.

What Is Fatty-Acid Acylation and How Does It Extend Half-Life?

Semaglutide employs a C18 fatty-acid acylation strategy: a C18 fatty-diacid chain is covalently attached to the GLP-1 peptide backbone via a mini-PEG linker at lysine position 34 (Lys³⁴). This modification achieves two simultaneous effects that together produce the ~7-day half-life:

• Albumin binding, The fatty-acid chain causes reversible, non-covalent binding to human serum albumin. Albumin-bound semaglutide circulates as a depot, releasing free drug slowly over time. Because albumin is too large for renal filtration at the glomerulus, albumin-bound semaglutide is protected from the rapid renal clearance that eliminates unmodified GLP-1.
• DPP-4 resistance, A substitution at position 8 of the peptide sequence (alanine → alpha-aminoisobutyric acid) renders semaglutide resistant to cleavage by DPP-4, the enzyme responsible for the rapid degradation of native GLP-1.

The result is a plasma half-life of approximately 165–184 hours (roughly 7 days), compared to 1–2 minutes for native GLP-1. This allows once-weekly subcutaneous dosing and, with appropriate formulation technology (co-formulation with SNAC permeation enhancer), once-daily oral dosing. A 2022 review by Aroda, Blonde, and Pratley in Reviews in Endocrine & Metabolic Disorders described semaglutide’s “low molecular weight, long half-life, and high potency” as the properties that made it an ideal candidate for oral delivery. [DOI: 10.1007/s11154-022-09735-8]

Pharmacokinetic characterization published by Marbury et al. in Clinical Pharmacokinetics (2017) investigated single-dose semaglutide 0.5 mg across renal function groups and found that semaglutide exposure was not meaningfully affected by mild-to-moderate renal impairment, an observation consistent with the albumin-binding mechanism reducing dependence on renal elimination pathways. [DOI: 10.1007/s40262-017-0528-2]

What Did the SUSTAIN Trials Show for Type 2 Diabetes?

The SUSTAIN program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is the pivotal phase 3 clinical trial series that established semaglutide’s efficacy and safety profile for glycemic management. The program enrolled more than 8, 000 patients across the spectrum of type 2 diabetes, ranging from treatment-naive patients to those on complex multi-drug regimens including basal insulin. All citations below are from articles retrieved from PubMed.

SUSTAIN 1, Monotherapy vs. Placebo

The SUSTAIN 1 phase 3a trial, published by Sorli et al. in The Lancet Diabetes & Endocrinology (2017), randomized 388 treatment-naive patients with type 2 diabetes to once-weekly subcutaneous semaglutide 0.5 mg, 1.0 mg, or placebo for 30 weeks. Semaglutide 0.5 mg reduced mean HbA1c by 1.45 percentage points versus 0.02 percentage points with placebo (estimated treatment difference −1.43%; p<0.0001); semaglutide 1.0 mg reduced HbA1c by 1.55 percentage points (estimated treatment difference −1.53%; p<0.0001). Mean body weight decreased by 3.73 kg and 4.53 kg respectively with 0.5 and 1.0 mg semaglutide, versus 0.98 kg with placebo. [DOI: 10.1016/S2213-8587(17)30013-X]

SUSTAIN 5, Semaglutide Added to Basal Insulin

SUSTAIN 5, published by Rodbard et al. in the Journal of Clinical Endocrinology and Metabolism (2018), evaluated semaglutide as an add-on to basal insulin in 397 patients with uncontrolled type 2 diabetes. At 30 weeks, mean HbA1c reductions were 1.4% and 1.8% for semaglutide 0.5 mg and 1.0 mg respectively, versus 0.1% for placebo (both p<0.0001). Mean body weight decreased by 3.7 kg, 6.4 kg, and 1.4 kg for semaglutide 0.5 mg, 1.0 mg, and placebo respectively. [DOI: 10.1210/jc.2018-00070]

SUSTAIN 7, Head-to-Head vs. Dulaglutide

SUSTAIN 7, published by Pratley et al. in The Lancet Diabetes & Endocrinology (2018), was an open-label phase 3b trial comparing semaglutide head-to-head with dulaglutide (a competing GLP-1 receptor agonist) in 1, 201 patients. At 40 weeks, semaglutide demonstrated statistically superior reductions in HbA1c and body weight versus dulaglutide at both the low-dose and high-dose comparisons (all p<0.0001). [DOI: 10.1016/S2213-8587(18)30024-X]

SUSTAIN Program Overview: Cardiovascular Safety

A 2019 synthesis by Aroda et al. in Diabetes & Metabolism reviewed SUSTAIN 1–7, noting that in SUSTAIN 6, the cardiovascular outcomes trial, semaglutide significantly reduced major adverse cardiovascular events versus placebo/standard of care (hazard ratio 0.74; p<0.001 for non-inferiority), representing a clinically important finding for a high-risk diabetic population. The review noted that semaglutide consistently demonstrated superior and sustained glycemic control and weight loss versus all comparators evaluated in the program. [DOI: 10.1016/j.diabet.2018.12.001]

What Did the STEP Trials Show for Weight Management?

The STEP program (Semaglutide Treatment Effect in People with obesity) evaluated once-weekly subcutaneous semaglutide 2.4 mg, a higher dose than the Ozempic formulations, specifically for chronic weight management in adults with obesity or overweight, with or without type 2 diabetes. These trials were the basis for the FDA approval of Wegovy.

STEP 3, Semaglutide Plus Intensive Behavioral Therapy

STEP 3, published by Wadden et al. in JAMA (2021), randomized 611 adults without diabetes to semaglutide 2.4 mg or placebo, both combined with a low-calorie diet for 8 weeks followed by 30 intensive behavioral therapy counseling sessions over 68 weeks. At week 68, estimated mean body weight change was −16.0% for semaglutide versus −5.7% for placebo (difference, −10.3 percentage points; p<0.001). 86.6% of semaglutide-treated participants lost at least 5% of baseline weight versus 47.6% with placebo. [DOI: 10.1001/jama.2021.1831]

STEP 4, Maintenance: What Happens If Treatment Continues vs. Stops?

STEP 4, published by Rubino et al. in JAMA (2021), investigated weight maintenance by randomizing 803 participants (after a 20-week semaglutide run-in with a mean weight loss of 10.6%) to continued semaglutide 2.4 mg or placebo for a further 48 weeks. Continued semaglutide produced an additional −7.9% mean weight change from week 20 to week 68, versus +6.9% (weight regain) in those switched to placebo, a difference of −14.8 percentage points (p<0.001). [DOI: 10.1001/jama.2021.3224]

STEP 8, Semaglutide vs. Liraglutide: A Head-to-Head Comparison

STEP 8, published by Rubino et al. in JAMA (2022), directly compared once-weekly subcutaneous semaglutide 2.4 mg to once-daily subcutaneous liraglutide 3.0 mg in 338 adults with overweight or obesity without diabetes. At 68 weeks, mean weight change was −15.8% with semaglutide versus −6.4% with liraglutide (difference, −9.4 percentage points; p<0.001). 70.9% of semaglutide participants achieved ≥10% weight loss versus 25.6% with liraglutide. [DOI: 10.1001/jama.2021.23619]

STEP 1 Extension, What Happens After Stopping Treatment?

A STEP 1 trial extension, published by Wilding et al. in Diabetes, Obesity & Metabolism (2022), followed a representative subset one year after treatment withdrawal. Participants who had achieved a mean weight loss of 17.3% during the 68-week active phase regained approximately two-thirds of that lost weight within one year of stopping semaglutide and lifestyle intervention, with cardiometabolic improvements reverting toward baseline. The authors noted these findings “confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.” [DOI: 10.1111/dom.14725]

What Is the Safety Profile Documented for Semaglutide?

A 2021 safety review by Smits and Van Raalte, published in Frontiers in Endocrinology, systematically reviewed adverse events from the SUSTAIN and PIONEER programs. The review found that semaglutide’s most common adverse events were gastrointestinal, predominantly nausea, diarrhea, and vomiting, typically mild-to-moderate and transient in nature. Semaglutide also increased the risk of biliary disease (cholelithiasis) relative to placebo. The review concluded that semaglutide has “an overall favorable risk/benefit profile for patients with type 2 diabetes” and that “no unexpected safety issues have arisen to date.” [DOI: 10.3389/fendo.2021.645563]

As with all prescription medications, the complete safety profile, including contraindications, warnings, and individual risk factors, requires evaluation by a prescribing clinician. This article does not summarize prescribing information and is not a substitute for FDA-approved labeling or professional medical guidance.

What Is Semaglutide’s Regulatory Status?

Semaglutide is a Schedule-unscheduled (non-controlled) prescription drug in the United States. It is not classified as a research chemical, not sold as a supplement, and is not legally available without a prescription from a licensed prescriber. Compounded semaglutide products, produced by compounding pharmacies, have been the subject of separate FDA guidance and enforcement actions; individuals should consult current FDA communications and their prescriber for guidance on compounded versions.

Frequently Asked Questions About Semaglutide

Is semaglutide FDA approved?

Yes. Semaglutide is an FDA-approved prescription medication marketed under the brand names Ozempic (type 2 diabetes), Rybelsus (type 2 diabetes, oral), and Wegovy (chronic weight management). All three require a valid prescription. Semaglutide is not available over the counter and is not a research chemical.

How does semaglutide work?

Semaglutide works as a GLP-1 receptor agonist. It binds to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, stimulating glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and signaling satiety in the hypothalamus. These four coordinated effects underlie its impact on both blood glucose levels and appetite regulation.

Why does semaglutide only need to be taken once weekly?

Semaglutide’s ~7-day half-life results from fatty-acid acylation: a C18 fatty-acid chain attached via a linker causes reversible albumin binding, protecting the peptide from renal clearance. An additional substitution at position 8 of the peptide sequence renders it resistant to DPP-4 enzymatic degradation. Together, these modifications extend the half-life approximately 5, 000-fold relative to native GLP-1.

What did the STEP trials study about semaglutide?

The STEP (Semaglutide Treatment Effect in People with obesity) phase 3 program evaluated once-weekly subcutaneous semaglutide 2.4 mg for chronic weight management in adults without type 2 diabetes. Multiple phase 3a and 3b trials published in JAMA (2021–2022) documented mean body weight reductions of approximately 15–16% from baseline over 68 weeks with semaglutide versus 5–6% with placebo when combined with lifestyle intervention, the evidence base that supported Wegovy’s FDA approval.

Educational reference only. Not medical advice. Semaglutide is an FDA-approved prescription medication (Ozempic, Wegovy, Rybelsus). This article documents publicly available clinical trial data and mechanism science for educational purposes only. It is not medical advice, does not recommend any course of treatment, does not provide dosing or titration guidance, and does not substitute for evaluation by a licensed healthcare professional. Decisions about prescription medications must be made in consultation with a qualified prescriber. All citations link to primary sources via DOI, read them in full. Must be 21+.